[Featured Stock] EID Rises on News of Sputnik Light Clinical Results Published in The Lancet

[Asia Economy Reporter Hyunseok Yoo] EID, which invested in Korea Corus, a contract manufacturer of Russian vaccines, is showing strong performance. This appears to be influenced by the news that the clinical paper on the single-dose Sputnik Light vaccine was published in The Lancet.

As of 1:50 PM on the 10th, EID was trading at 327 KRW, up 1.55% (5 KRW) compared to the previous trading day.

According to the medical journal The Lancet, a clinical paper by more than 30 scientists including Amir I. Tukhvatulin was published. According to the paper, the single-dose Sputnik Light showed excellent safety and immunogenicity.

Clinical results from the Gamaleya Institute involving 28,000 local residents in Moscow showed that the Sputnik Light vaccine demonstrated 70% efficacy against the Delta variant of the coronavirus for three months after vaccination, and 75% efficacy in subjects under 60 years old.

The single-dose vaccine Sputnik Light has currently been approved in 15 countries, and approval or registration procedures are underway in more than 30 additional countries, according to the Russian sovereign wealth fund RDIF’s website.

According to the clinical results of Sputnik Light, the COVID-19 prevention rate is 70%, and 75% in those under 60 years old.

The Sputnik Russian vaccine is produced domestically, and currently, shipments of 7.5 million doses are being prepared.

Korea Corus is preparing to produce the Sputnik vaccine by forming a consortium with domestic pharmaceutical and bio companies such as Isu Abxis and Chong Kun Dang Bio. The Korea Corus consortium is expected to produce up to 500 million doses of the vaccine.